The global aneurysmal subarachnoid hemorrhage drugs market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Aneurysmal subarachnoid hemorrhage (aSAH) is a life-threatening type of stroke. It is caused by bleeding in the space surrounding the brain. It mostly occurs due to bursts and leaks of a weak area in a blood vessel on the surface of the brain due to which blood builds up around the brain and inside the skull increasing pressure on the brain. The major factor driving the demand for aneurysmal subarachnoid hemorrhage drugs is the increasing geriatric population and the high prevalence of populations suffering from hypertension across the globe.

According to the Center for Disease Control and Prevention, nearly half of adults or 47%, or 116 million have hypertension which is defined as a systolic blood pressure greater than 130 mmHg or diastolic blood pressure greater than 80 mmHg or are taking medication for hypertension in the US. Additionally, about 1 in 4 adults (24%) with hypertension have their condition under control and about half of the adults or 45% or 37 million with uncontrolled hypertension have a blood pressure of 140/90 mmHg or higher in the US. Furthermore, about 34 million adults are recommended to take medication and about two out of three of this group or 19 million have a blood pressure of 140/90 mmHg or higher. Hence, the increasing prevalence of hypertension is creating a risk for aneurysmal subarachnoid hemorrhage which is driving the demand for these drugs.

Some major players in the market include Johnson & Johnson Services, Inc., Pfizer Inc., and Mylan N.V., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in November 2020, Idorsia Ltd. announced positive top-line results of the Japanese registration program which investigated clazosentan in adult Japanese patients post aneurysmal subarachnoid hemorrhage (aSAH).

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028

Segment Covered- 

• By Type

Regions Covered-

• North America
• Europe
• Asia-Pacific
• Rest of the World

Competitive Landscape- Johnson & Johnson Services, Inc., Pfizer Inc., and Mylan N.V., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Aneurysmal Subarachnoid Hemorrhage Drugs Market Report by Segment

By Type

• Opioid Analgesic
• Calcium Channel Blocker
• Anticonvulsant
• Stool Softener
• Osmotic agents/diuretics
• Other

Global Aneurysmal Subarachnoid Hemorrhage Drugs Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe 

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific 

Rest of the World

• Latin America 
• Middle East & Africa